Cargando…
Low-dose interleukin-2 therapy in systemic lupus erythematosus
In systemic lupus erythematosus (SLE), T regulatory cells (T(regs)) contribute to the inhibition of autoimmune responses by suppressing self-reactive immune cells. Interleukin (IL)-2 plays an essential role in the generation, function and homeostasis of the T(regs) and is reduced in SLE. Several cli...
Autor principal: | La Cava, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538619/ https://www.ncbi.nlm.nih.gov/pubmed/37781677 http://dx.doi.org/10.2478/rir-2023-0021 |
Ejemplares similares
-
Systemic Lupus Erythematosus and Coronavirus Disease 2019
por: Cava, Antonio La
Publicado: (2021) -
T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy
por: Mak, Anselm
Publicado: (2022) -
Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus
por: Wang, Naidi, et al.
Publicado: (2023) -
The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus
por: Wang, Bing, et al.
Publicado: (2023) -
Leptin Enhances Availability of Apoptotic Cell-Derived Self-Antigen in Systemic Lupus Erythematosus
por: Amarilyo, Gil, et al.
Publicado: (2014)